The global allergy diagnostics and therapeutics market accounted for USD 33.10 billion in 2023 and is expected to reach at USD 104.53 billion by 2034 with a CAGR of 11.02% during the forecast period 2024-2034. The development of novel medicines, increased awareness and diagnosis rates, growing prevalence of allergic illnesses, technological integration and digital health, and improvements in diagnostic technologies will propel market expansion.
Worldwide, the frequency of allergies is rising due to several factors such as dietary habits, pollution, and lifestyle changes. As allergies increase, there is a corresponding rise in the need for diagnostic procedures and available therapies. Allergy identification is becoming simpler with the advent of new, more precise testing technologies. New blood testing, molecular allergy diagnostics, and skin prick tests are some of these developments. For instance, Thermo Fisher Scientific announced in April 2024 the introduction of Thermo Scientific ImmunoCAP Specific IgE Allergen Components, a new allergy testing solution.
By type, the therapeutics segment accounted for the highest revenue-grossing segment in the global allergy diagnostics and therapeutics market in 2023 owing to the rising prevalence of allergic diseases, advancements in therapeutic options, and increased adoption of personalized medicine approaches. For instance, Siemens Healthineers released the ADVIA Centaur sAST Assay, a diagnostic tool for allergy testing, in March 2023. Additionally, the diagnostic segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in diagnostic technologies, increasing awareness of early diagnosis, and the integration of digital health solutions.
By allergen type, the inhaled segment accounted for the highest revenue-grossing segment in the global allergy diagnostics and therapeutics market in 2023 owing to the high prevalence of respiratory allergies and asthma, coupled with the effectiveness and widespread use of inhaled treatments. For instance, Omega Diagnostics announced in September 2023 that its VISITECT® CD4 Advanced Disease test - which is used in allergy diagnostics - had received the CE Mark registration. Additionally, the drug allergies segment is estimated to grow at the fastest CAGR during the forecast period owing to the rising prevalence of adverse medication responses and the expanding demand for precise diagnostic procedures as well as efficient drug allergy therapies.
By test type, the in vitro test segment accounted for the highest revenue-grossing segment in the global allergy diagnostics and therapeutics market in 2023 owing to the higher accuracy, reliability, and growing demand of laboratory-based testing for allergy diagnostics. For instance, in January 2023, the FDA approved ALK's expanded use of ODACTRA, a sublingual immunotherapy pill, for treating teenagers aged 12 to 17 who have allergic rhinitis caused by house dust mites. Additionally, the in vivo test segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for precise and immediate results in allergy diagnostics and the growing use of skin prick tests.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global allergy diagnostics and therapeutics market in 2023 owing to the availability of advanced diagnostic equipment, specialized medical professionals, and comprehensive allergy treatment options in hospital settings. For instance, in October 2022, Allergy Partners partnered with Aimmune Therapeutics to provide patients ages 4-17 with direct access to PALFORZIA, an FDA-approved medication for peanut allergies. Allergy Partners Therapeutics (APT) will distribute PALFORZIA throughout its nationwide network. Additionally, the diagnostic labs segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for specialized and accurate allergy testing services and the expansion of diagnostic lab networks.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of allergic conditions, advanced healthcare infrastructure, and significant investment in research and development. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the growing acceptance of cutting-edge diagnostic and treatment options, the advancement of healthcare infrastructure, and the growing awareness of allergy disorders. For instance, in August 2022, the FDA approved Thermo Fisher Scientific's ImmunoCAP blood tests for the detection of sesame and wheat allergies. The company says that in vitro diagnostic tests can help a lot of patients avoid unnecessary dietary restrictions by differentiating between wheat sensitization and grass cross-reactivity by identifying specific antibodies.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Worldwide, the frequency of allergies is rising due to several factors such as dietary habits, pollution, and lifestyle changes. As allergies increase, there is a corresponding rise in the need for diagnostic procedures and available therapies. Allergy identification is becoming simpler with the advent of new, more precise testing technologies. New blood testing, molecular allergy diagnostics, and skin prick tests are some of these developments. For instance, Thermo Fisher Scientific announced in April 2024 the introduction of Thermo Scientific ImmunoCAP Specific IgE Allergen Components, a new allergy testing solution.
By type, the therapeutics segment accounted for the highest revenue-grossing segment in the global allergy diagnostics and therapeutics market in 2023 owing to the rising prevalence of allergic diseases, advancements in therapeutic options, and increased adoption of personalized medicine approaches. For instance, Siemens Healthineers released the ADVIA Centaur sAST Assay, a diagnostic tool for allergy testing, in March 2023. Additionally, the diagnostic segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in diagnostic technologies, increasing awareness of early diagnosis, and the integration of digital health solutions.
By allergen type, the inhaled segment accounted for the highest revenue-grossing segment in the global allergy diagnostics and therapeutics market in 2023 owing to the high prevalence of respiratory allergies and asthma, coupled with the effectiveness and widespread use of inhaled treatments. For instance, Omega Diagnostics announced in September 2023 that its VISITECT® CD4 Advanced Disease test - which is used in allergy diagnostics - had received the CE Mark registration. Additionally, the drug allergies segment is estimated to grow at the fastest CAGR during the forecast period owing to the rising prevalence of adverse medication responses and the expanding demand for precise diagnostic procedures as well as efficient drug allergy therapies.
By test type, the in vitro test segment accounted for the highest revenue-grossing segment in the global allergy diagnostics and therapeutics market in 2023 owing to the higher accuracy, reliability, and growing demand of laboratory-based testing for allergy diagnostics. For instance, in January 2023, the FDA approved ALK's expanded use of ODACTRA, a sublingual immunotherapy pill, for treating teenagers aged 12 to 17 who have allergic rhinitis caused by house dust mites. Additionally, the in vivo test segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for precise and immediate results in allergy diagnostics and the growing use of skin prick tests.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global allergy diagnostics and therapeutics market in 2023 owing to the availability of advanced diagnostic equipment, specialized medical professionals, and comprehensive allergy treatment options in hospital settings. For instance, in October 2022, Allergy Partners partnered with Aimmune Therapeutics to provide patients ages 4-17 with direct access to PALFORZIA, an FDA-approved medication for peanut allergies. Allergy Partners Therapeutics (APT) will distribute PALFORZIA throughout its nationwide network. Additionally, the diagnostic labs segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for specialized and accurate allergy testing services and the expansion of diagnostic lab networks.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of allergic conditions, advanced healthcare infrastructure, and significant investment in research and development. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the growing acceptance of cutting-edge diagnostic and treatment options, the advancement of healthcare infrastructure, and the growing awareness of allergy disorders. For instance, in August 2022, the FDA approved Thermo Fisher Scientific's ImmunoCAP blood tests for the detection of sesame and wheat allergies. The company says that in vitro diagnostic tests can help a lot of patients avoid unnecessary dietary restrictions by differentiating between wheat sensitization and grass cross-reactivity by identifying specific antibodies.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Allergen Type, Test Type, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Allergy Diagnostics and Therapeutics Market Report 2023 - 2034
Allergy Diagnostics and Therapeutics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Diagnostics
- Instruments
- Consumables
- Services
- Therapeutics
- Antihistamines
- Decongestants
- Corticosteroids
- Mast Cell Stabilizers
- Leukotriene Inhibitors
- Nasal Anti-cholinergic
- Immuno-modulators
- Epinephrine
- Immunotherapy
Allergy Diagnostics and Therapeutics Market Analysis & Forecast by Allergen Type 2023 - 2034 (Revenue USD Bn)
- Food
- Dairy Products
- Poultry Product
- Tree Nuts
- Peanuts
- Shellfish
- Wheat
- Soys
- Other Food Allergens
- Inhaled
- Drug
- Other Allergens
Allergy Diagnostics and Therapeutics Market Analysis & Forecast by Test Type 2023 - 2034 (Revenue USD Bn)
- In vivo Test
- Skin Prick Test
- Intradermal Test
- Patch Test
- In vitro Test
Allergy Diagnostics and Therapeutics Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Diagnostics Labs
- Research & Development Centers
- Others
Allergy Diagnostics and Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Allergy Diagnostics and Therapeutics Market: Type Estimates & Trend Analysis
8. Allergy Diagnostics and Therapeutics Market: Allergen Type Estimates & Trend Analysis
9. Allergy Diagnostics and Therapeutics Market: Test Type Estimates & Trend Analysis
10. Allergy Diagnostics and Therapeutics Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Allergy Diagnostics and Therapeutics Market
13. Europe Global Allergy Diagnostics and Therapeutics Market
14. Asia Pacific Global Allergy Diagnostics and Therapeutics Market
15. Latin America Global Allergy Diagnostics and Therapeutics Market
16. MEA Global Allergy Diagnostics and Therapeutics Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Siemens Healthineers
- Danaher Corporation (Beckman Coulter)
- Stallergenes Greer
- Omega Diagnostics Group PLC
- bioMérieux SA
- HAL Allergy Group
- Lincoln Diagnostics Inc.
- Hycor Biomedical
- Hitachi Chemical Diagnostics Inc.
- HOB Biotech Group Corp.
- EUROIMMUN AG (A PerkinElmer Company)
- R-Biopharm AG
- Indoor Biotechnologies Inc.
- Quest Diagnostics Incorporated.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 33.1 Billion |
| Forecasted Market Value ( USD | $ 104.53 Billion |
| Compound Annual Growth Rate | 11.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
